Cancer Pipelines Shrink as Incyte, iTeos Cut Candidates Following Disappointing Data
Incyte is abandoning its ALK2 blocker zilurgisertib, which it was trialing for myelofibrosis-associated anemia, while iTeos will deprioritize the development of inupadenant after it failed to meet the biotech’s clinical bar in a Phase II study of metastatic non-small cell lung cancer.
Cancer Pipelines Shrink as Incyte, iTeos Cut Candidates Following Disappointing Data Read More »
